Abstract：Nowadays, hypertension as one of the major global public health burdens, affects 200 million Chinese and 1 billion people worldwide. To date, the treatment of resistant hypertension remains a great challenge in the management of hypertension. In recent years, represented by the SymplicityTM System, Catheter-based renal denervation (RDN), specifically targeting renal sympathetic nerves, has become a novel technique for the treatment of resistant hypertension with great promises. Nonetheless, defects of this novel technique are also obvious, e.g. low efficiency, prolongation of operative time and radiation exposure time due to the only strategic option of point by point ablation, etc. While on the other hand, with the rapid developments of new ablation systems, more and more catheter ablation systems with greater safety and efficacy have become available. This review will focus on the developments of radiofrequency ablation catheter system, radiofrequency ablation balloon system and chemical ablation, which are all closely related to RDN.
卢成志，宋立军. 新型经导管去肾交感神经器械研发进展[J]. 中国医疗设备, 2014, 29(5): 1-4.
LU Cheng-zhi, SONG Li-jun. Research Progress of Catheter-based Renal Denervation Devices. China Medical Devices, 2014, 29(5): 1-4.
Brandt MC,Mahfoud F,Reda S,et al.Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension[J]. J Am Coll Cardiol,2012,59(10):901-909.
[1]
刘力生.中国高血压防治指南2010[J].中华高血压杂志,2011, (8):701-743.
[3]
Esler MD,Krum H,Sobotka PA,et al.Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial[J].Lancet,2010,376(9756):1903-1909.
[2]
Krum H,Schlaich M,Whitbourn R,et al.Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J].Lancet,2009, 373(9671):1275-1281.
[8]
Witkowski A,Prejbisz A,Florczak E,et al.Effects of renal sympathetic denervation on blood pressure,sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea[J].Hypertension, 2011,58(4):559-565.
[4]
Krum H,Barman N,Schlaich M,et al.Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months[J].Hypertension, 2011,57(5):911-917.
[5]
Esler MD,Krum H,Schlaich M,et al.Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension:One-Year Results From the Symplicity HTN-2 Randomized,Controlled Trial[J].Circulation, 2012,126(25):2976-2982.
[7]
Mahfoud F,Schlaich M,Kindermann I,et al.Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension:a pilot study[J].Circulation, 2011,123(18):1940-1946.
